These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 9400943)

  • 1. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
    Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
    Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
    Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
    Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
    Ma J; Verweij J; Planting AS; de Boer-Dennert M; van Ingen HE; van der Burg ME; Stoter G; Schellens JH
    Br J Cancer; 1995 Mar; 71(3):512-7. PubMed ID: 7880732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
    Schellens JH; Ma J; Planting AS; van der Burg ME; van Meerten E; de Boer-Dennert M; Schmitz PI; Stoter G; Verweij J
    Br J Cancer; 1996 Jun; 73(12):1569-75. PubMed ID: 8664132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
    Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
    Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
    Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
    Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
    Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E
    Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
    van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
    Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
    Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
    Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
    Jarvis IW; Meczes EL; Thomas HD; Edmondson RJ; Veal GJ; Boddy AV; Ottley CJ; Pearson DG; Tilby MJ
    Biochem Pharmacol; 2012 Jan; 83(1):69-77. PubMed ID: 22015635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
    Tonda ME; Murry DJ; Rodman JH
    Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The formation and persistence of carboplatin-DNA adducts in rats.
    Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
    Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
    Perez RP; Chen E; Thaddeus Beck J; Shirai K; Neil Hayes D; Shen T; Baldwin JR; Bryant KB; He S; Chin S
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00519. PubMed ID: 31788317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.